Treatment Of Idiopathic Pulmonary Fibrosis

Publication Date: July 1, 2015

Key Points

Key Points

  • Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause occurring in adults.
  • Radiologic and/or histopathologic patterns are consistent with usual interstitial pneumonia.
  • Significant advances have been recently made in the clinical management of IPF.
  • All of the recommendations in favor of treatment are conditional, meaning that decisions to treat patients with IPF should be individualized. Clinicians should be cautious to not interpret recommendations with the same grade as having the same net effects.
  • The recommendations in favor of treatment put a higher value on the potential benefit of patient-important outcomes such as disease progression as measured by FVC decline and mortality and a lower value on potentially significant adverse effects and the cost of treatment.

Treatment

...reatment

...mended DrugsaHaving trouble viewing tab...


...ble 2. Recommend...

...patients with IPF, the guideline committee recomm...

...T use imatinib. ( Moderate , S, M)695...

...cians NOT use warfarin anticoagulation in p...

...icians NOT use the combination therapy of N-acetyl...

...cians NOT use ambrisentan, a selective ER-A end...

...or patients with IPF, the guideline committe...

...nintedanib. ( Moderate , C, M)695

...use pirfenidone. ( Moderate , C, M)695...

...ans NOT use sildenafil, a phosphod...

...inicians NOT use bosentan or macitentan, both dua...

...NOT use N-acetylcysteine monotherapy. ( Low , C, L...

Clinicians use regular anti-acid treatment. ( Very...